Subtyping NSCLC Using Antibody Cocktail Napsin A/p60
Research type
Research Study
Full title
The Use of Napsin A/p40 Antibody Cocktail to Subtype Non-Small Cell Lung Carcinoma on Cytology Endobronchial Ultrasound (EBUS) – Transbronchial Needle Aspirations (TBNA) Samples
IRAS ID
227409
Contact name
Miguel Perez--Machado
Contact email
Sponsor organisation
Royal Free London Foundation NHS Trust
Duration of Study in the UK
0 years, 3 months, 29 days
Research summary
The subtyping of non-small cell carcinomas into either adenocarcinomas (ACA) or squamous cell carcinomas (SQCC)is essential for the treatment of patients suffering with this lung disease as the treatment paths vary considerably for each type and may involve surgery, radiotherapy and/or chemotherapy. The swift diagnosis of the type is beneficial for both patient and clinician. A recent study by Nishino et al., shows the usefulness of a two-antibody cocktail, Napsin A/p40, on cytology samples which can determine if a tumour is ACA or SQCC on small amounts of material and still leave tissue available for molecular analysis. This study is using Endobronchial Ultrasound (EBUS)-Transbronchial Needle Aspirates (TBNA) samples received at the Royal Free Hospital (RFH) to assess the two-antibody cocktail on known ACA and SQCC specimens. The study will then statistically analyse its accuracy with a view to employing the antibody cocktail in routine clinical practice reporting. The study will be conducted in the cellular pathology laboratories at The Royal Free Hospital and will last approximately 5 months.No patients or new samples will be needed for this study as all material used will be from previously reported samples taken during routine diagnostic care from approximately the last two years.
REC name
Wales REC 7
REC reference
17/WA/0326
Date of REC Opinion
11 Oct 2017
REC opinion
Favourable Opinion